ZA200208628B - Inhibition of angiogenesis and tumor growth. - Google Patents
Inhibition of angiogenesis and tumor growth. Download PDFInfo
- Publication number
- ZA200208628B ZA200208628B ZA200208628A ZA200208628A ZA200208628B ZA 200208628 B ZA200208628 B ZA 200208628B ZA 200208628 A ZA200208628 A ZA 200208628A ZA 200208628 A ZA200208628 A ZA 200208628A ZA 200208628 B ZA200208628 B ZA 200208628B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- substance
- composition
- covalent bond
- cis
- Prior art date
Links
- 230000004614 tumor growth Effects 0.000 title claims description 25
- 230000014399 negative regulation of angiogenesis Effects 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims description 143
- 239000000203 mixture Substances 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 49
- 102000006495 integrins Human genes 0.000 claims description 49
- 108010044426 integrins Proteins 0.000 claims description 49
- 239000000126 substance Substances 0.000 claims description 42
- 230000033115 angiogenesis Effects 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 230000003993 interaction Effects 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 26
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 25
- 230000002401 inhibitory effect Effects 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 238000001990 intravenous administration Methods 0.000 claims description 21
- 230000005764 inhibitory process Effects 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- -1 3- cyclohexyl Chemical group 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 238000007912 intraperitoneal administration Methods 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- 238000007918 intramuscular administration Methods 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000007919 intrasynovial administration Methods 0.000 claims 8
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 3
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 3
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 70
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 70
- 229940125904 compound 1 Drugs 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 18
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 17
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 12
- 229940125797 compound 12 Drugs 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 10
- 229940126214 compound 3 Drugs 0.000 description 10
- 239000011734 sodium Substances 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 229940125898 compound 5 Drugs 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 6
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical class NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- FDQSRULYDNDXQB-UHFFFAOYSA-N benzene-1,3-dicarbonyl chloride Chemical compound ClC(=O)C1=CC=CC(C(Cl)=O)=C1 FDQSRULYDNDXQB-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 230000002491 angiogenic effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 4
- BXGTVNLGPMZLAZ-UHFFFAOYSA-N n'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000011382 collagen catabolic process Effects 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 238000007805 zymography Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MOOUWXDQAUXZRG-UHFFFAOYSA-N 4-(trifluoromethyl)benzyl alcohol Chemical compound OCC1=CC=C(C(F)(F)F)C=C1 MOOUWXDQAUXZRG-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 125000006847 BOC protecting group Chemical group 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QEVGZEDELICMKH-UHFFFAOYSA-N Diglycolic acid Chemical compound OC(=O)COCC(O)=O QEVGZEDELICMKH-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 229940124761 MMP inhibitor Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 description 2
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001745 anti-biotin effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- QZUPTXGVPYNUIT-UHFFFAOYSA-N isophthalamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=C1 QZUPTXGVPYNUIT-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- ZLYYJUJDFKGVKB-OWOJBTEDSA-N (e)-but-2-enedioyl dichloride Chemical compound ClC(=O)\C=C\C(Cl)=O ZLYYJUJDFKGVKB-OWOJBTEDSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 101710082662 Matrix metalloproteinase-C Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 241000949477 Toona ciliata Species 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- FYXKZNLBZKRYSS-UHFFFAOYSA-N benzene-1,2-dicarbonyl chloride Chemical compound ClC(=O)C1=CC=CC=C1C(Cl)=O FYXKZNLBZKRYSS-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000006480 benzoylation reaction Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 150000001723 carbon free-radicals Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000000477 gelanolytic effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- WMCFGPHWGVXGOY-UHFFFAOYSA-N hexanoic acid;hydrochloride Chemical compound Cl.CCCCCC(O)=O WMCFGPHWGVXGOY-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002531 isophthalic acids Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- YHWWZMAZRZSUJA-HNNXBMFYSA-N methyl (2s)-2-benzamido-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoate Chemical compound CC(C)(C)OC(=O)NCCCC[C@@H](C(=O)OC)NC(=O)C1=CC=CC=C1 YHWWZMAZRZSUJA-HNNXBMFYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Description
r 3
INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
This invention relates to compositions for inhibiting angiogenesis and tumor growth. More particularly, the invention relates to compositions that bind to integrin «3; and block the interaction of integrin a. 8; with matrix metalloproteinase 2 (MMP2). The invention also relates to methods of inhibiting angiogenesis and tumor growth utilizing selective inhibitors of the binding of integrin «,B, with MMP2.
Invasion of vascular cells into tissues requires the coordinated interplay of numerous factors including proteinases, which remodel the extracellular matrix architecture, as well as cell adhesion molecules that recognize this provisional matrix. Recent reports have implicated that the 72 kDa matrix metalloproteinase 2 (MMP2) is a key player in vascular development and angiogenesis. For example, Kitoh ez al. (J. Cell Sci., 109, 953-8 (1996)) report that MMP?2 and its activator membrane type 1-matrix metalloproteinase (MT1-
MMP) are coordinately expressed by mesenchymal cells almost exclusively during embryonic development, indicating specific matrix remodeling constraints in these tissues. In addition, angiogenesis and corresponding tumor growth are reduced in MMP2 knockout mice (see Itoh et al., Cancer Res., 58 1048-51 (1998)). Interestingly, Saftor et al. (Proc. Natl. Acad. Sci. U.S.A., 89, 1557-61 (1992)) have shown that ligation of the integrin a, ,, itself a known mediator of angiogenesis, induces MMP2 production, suggesting a coordinated interplay of these two molecules during the vascular remodeling associated with blood vessel formation (see also Bafetti et al., J. Biol. Chem., 273, 143-9 (1998)). In fact, direct interaction between MMP2 and integrin a, 3; has been demonstrated by
Brooks et al. (Cell, 85, 683-93 (1996)). The negative regulation of MMP2 during vascular invasion and maturation was later shown by Brooks ez al. to be dependent upon expression of «3; (Cell, 92, 391-400 (1998)).
rr
Although inhibition of angiogenesis and concomitant suppression - of tumor growth by natural as well as synthetic inhibitors of MMP’s, including
MMP2, has been documented, the translation of such strategies into clinical modalities has met with limited success, primarily due to the deleterious side effects of such broad spectrum inhibitors. Since MMP function, in general, may be required for many processes in the adult organism, active site inhibition of enzymatic function is likely to have far reaching effects on various biological processes involving tissue remodeling, such as wound healing. In fact, it has been documented that therapies with broad spectrum MMP inhibitors in clinical studies of various cancer types cause severe side effects, including inflammatory tendinitis, polyarthritis, and muscoskeletal pain syndromes, which are dose limiting and often persist after discontinuation of therapy. Given the limited distribution of integrin o,f; in adult organisms, however, one would predict that targeting the interaction between MMP2 and op; to the areas of neovascularization or cellular invasion should correspondingly limit the effects of such treatment-related toxicities. Indeed, the recombinant non-catalytic carboxy- terminal hemopexin domain of MMP2 (PEX), which mediates MMP2 binding to integrin «,f;, has shown antiangiogenic and antitumor activity in vivo. The potential utility of such a large protein fragment, but with attendant shortcomings (e.g. large scale production problems, FDA quality and safety control issues and antigenicity), suggested the need for a more practical solution to this problem.
There is a need therefore, for chemical compounds that selectively inhibit MMP activity at tumor growth sites with minimal inhibition of MMP in : other regions of the body.
The present invention provides novel compounds useful as inhibitors of angiogenesis and tumor growth. The invention also provides a method for the inhibition of the interaction of MMP2 with integrin «3; and a method for inhibition of angiogenesis in cells containing integrin «,p,. Further, the invention provides a method for inhibition of tumor growth by administration of MMP2-¢ 3; interaction inhibitors.
The compounds of the present invention are represented by . Formula (I) and include glycyl lysine derivatives chemically attached to a linking group: : 5
H a—z—L, 3 (PP N
Y ih SUN ni m @ s2 0 o G' 10° t wherein G! and G? are each independently -NH-C(0)-O-R’, -NH-C(0)-0-(CH),C4H)-X', -NH-C(0)-NH-(CHy),-(CH)-X', -0-C(0)-NH~(CH,),«(CsH,)-X',-0-C(0)-0-(CH,),-(C;H,)-X', or -NH-C(0)-CH,-(C,H,)-X"; Y' and Y? are each independently OH, C,- C, alkyl,
C,- C, hydroxyalkyl, C,- C, alkoxy, phenyl, benzyl, or -NH,; R! is C,- C, alkyl;
X! is halo, nitro, C,- C, alkyl, C,- C, alkoxy, or C,- C, perfluoroalkyl; Z is -C=C-, -CH,-, cis -CH=CH-, trans -CH=CH-, cis -CH,-CH=CH-CH,-, trans -CH,-CH=CH-CH,-, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3-cyclohexyl, cis- 1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each independently an integer having a value of 0 or 1; t is an integer having a value of O or 1; and v is an integer having a value of 1 or 2; with provisos that when A is H, t is 0; when A is a covalent bond, tis 1; when mis 0, Y'is C,- C, hydroxyalkyl; and when n is 0, Y? is C, - C, hydroxyalkyl. These compounds bind to «,B; and inhibit the interaction of MMP2 with «35.
Preferred compounds of structural Formula (I) are represented in structural Formula (II):
LS §
CoA iJ TOON on 0 : lo] "Ny
NN Z
Xoo x, 10° wherein R? and R® are each independently H, C, - C, alkyl, phenyl or benzyl; X* and X? are each independently halo, nitro, C, - C, alkoxy, C, - C, alkyl, or C, -
C, perfluoroalkyl; A is H or a covalent bond; and t is an integer having a value of 0 or 1; with the proviso that when A is H, t is 0 and when A is a covalent bond, tis 1. When A is a covalent bond and t is 1, the glycyl lysine derivative moieties may be attached to the benzene linking group in the ortho, meta or para position.
When compounds of Formulas (I) and (II) are administered to cells containing «,B,, the binding of c.f; with MMP?2 is inhibited, thus interfering with an essential mechanism in angiogenesis. Interference with angiogenesis can also inhibit tumor growth by preventing vascularization of the tumor, thus starving it of nutrition. The angiogenesis and tumor growth inhibiting compounds of the present invention are thus useful therapeutic agents for the . treatment of patients with tumors or angiogenic disorders. Because the present compounds bind to «,f,, these compounds can also be used to suppress inflammatory events.
Co "The compounds of the present invention may be formulated in suitable pharmaceutically acceptable media to afford pharmaceutical compositions useful for the treatment of tumors and other disorders involving undesired angiogenesis.
In a method aspect of the present invention, pharmaceutical compositions containing the compounds of Formulas (I) and (II) are prepared by
~5- formulating the compound in a pharmaceutically acceptable matrix. The _ pharmaceutical compositions of the active compounds are administered to a patient with a tumor to reduce or eliminate tumor growth. The active compounds can be administered parenterally by injection or by gradual infusion over time, or by any other method suitable for the particular dosage form.
In the accompanying drawings:
FIG. 1 is a schematic illustration depicting MMP2 interaction with integrin a, f3, and its role in angiogenesis as well as the inhibition of MMP2 interaction with «3; by an antagonist such as the compounds of the present invention.
FIG. 2A graphically illustrates the effect of inhibitor compounds of
Formula (I) on MMP2 interaction with integrin «,B; in a solid phase binding assay.
FIG. 2B illustrates the binding of compounds of Formula (I) on with integrin «,B; and a,f,.
FIG. 2C compares the effect of a compound of the present invention with a control compound on binding to 3.
FIG. 2D compares the effect of amino acid residues RGD on binding of a present compound to cB; with the effect of RGD on binding of bVN to af.
FIG. 3A graphically illustrates proteinase activity in B, positive cells and in f3; negative cells.
FIG. 3B illustrates MMP2 binding in f3, positive cells and {3, negative cells.
FIG. 4A is a microscopic depiction of angiogenesis inhibition in
Chick CAM tissue. }
FIG. 4B is a graphical illustration of angiogenesis inhibition in
Chick CAM tissue.
FIG. 4C depicts the levels of MMP2 in treated and untreated cells.
FIG. 5A is a microscopic depiction of tumor growth and vasculature in Chick CAM tissue.
FIG. 5B is a microscopic depiction of blood vessel density in :
Chick CAM tissue.
FIG. 5C is graphical illustration of tumor weight in Chick CAM tissue.
FIG. 5D is a graphical illustration of vascularization in Chick
CAM tissue.
FIG. 5D is a microscopic depiction of tumor cell density in Chick
CAM tissue.
Detailed Description of the Invention 10° The binding of MMP? to integrin af, is an important mechanism in the process of angiogenesis. Specific inhibition of this binding interaction results in a reduction in vascularization in growing tissues such as tumors, and thus retards tumor growth. The interaction of MMP2 with integrin o,f, is illustrated pictorially in FIG. 1. A new class of angiogenesis and tumor growth inhibitors, are small molecule antagonists described below, that specifically interfere with the binding of MMP? to integrin o.,f,, thus affording an important new treatment tool.
Certain compounds of this invention may possess one or more asymmetric centers and may exist in optically active forms. Additional asymmetric centers may be present in a substituent group, such as an alkyl group.
Pure S-isomers and pure R-isomers, racemic mixtures of the isomers, and mixtures thereof are intended to be within the scope of this invention. Chiral forms of certain compounds of this invention are contemplated, and are : specifically included within the scope of this invention.
The term "alkoxy" means an oxygen atom linked by an ether bond to an alkyl group, as defined below, of the size indicated. Examples of alkoxy groups are methoxy, ethoxy, t-butoxy, and the like. The term "alkyl" means a - straight- or branched-chain carbon radical of the size indicated. Representative of alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, 2-ethylhexyl, n-octyl, 2,4-dimethylpentyl, and the like. The term "hydroxyalkyl" means an alkyl group, as defined above, of the size indicated,
attached to a hydroxyl group. Examples include hydroxymethyl, 2-hydroxyethyl, : 3-hydroxy-1-propyl, 2-hydroxy-1-propyl, 4-hydroxybutyl, and the like.
The term "perfluoroalkyl” refers to a alkyl group of the size indicated, as defined below, bearing fluoro substituents in place of each hydrogen, for example trifluoromethyl and pentafluoroethyl. :
The terms "halo" or "balogen" refer to bromo, chloro, fluoro and iodo.
The compounds of the present invention are represented by
Formula (I) and include glycyl lysine derivatives chemically attached to a linking 10° group: ) H zl, 0 | SOS ni m 2 © G 6’ M t wherein G' and G* are each independently -NH-C(0)-O-R!, -NH-C(0)-0-(CH,),~(CsH)-X", -NH-C(0)-NH-(CH,),~(C:H,)-X", -0-C(0)-NH~(CH,) ACH,)-X!, -0-C(0)-0-(CH,),(CH,)-X", or -NH-C(0)-CH,~(C,H,)-X'; Y'! and Y? are each independently OH, C,- C, alkyl,
C,- C, hydroxyalkyl, C,- C, alkoxy, phenyl, benzyl, or -NH,; R' is C,- C, alkyl;
X! is halo, nitro, C,- C, alkyl, C,- C, alkoxy, or C,- C, perfluoroalkyl; Z is -C=C-, -CH,-, cis -CH=CH-, trans -CH=CH-, cis -CH,-CH=CH-CH,-, trans -CH,-CH=CH-CH,-, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3-cyclohexyl, Cis- 1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each independently an integer having a value of O or 1; t is an integer having a value of 0 or 1; and v is an integer having a value of 1 or 2; with provisos that when A is H, t is 0; when A is a covalent bond, t is 1; when m is 0, Y' is C, - C, hydroxyalkyl; and when n is 0, Y? is C, - C, hydroxyalkyl.
Preferably G' and G* are -NH-C(0)-0-(CH,),-(CH,)-X!, Y! and
Y? are OH, and m and n are 1. Preferably, X' is C,- C, perfluroalkyl, most preferably trifluoromethyl. Preferred compounds within the purview of - structural Formula (I) are represented in structural Formula (I) and include glycyl lysine derivatives attached to a benzene linking group in either the ortho, meta or para orientation:
A
Lode J ~ Coe R? ©
I o” y lo] lo} HN : 7
SX, | x, wherein R? and R® are each independently H, C, - C, alkyl, phenyl or benzyl; X* and X? are each independently halo, nitro, C, - C, alkoxy, C, ~ C, alkyl, or C, - : C, perfluoroalkyl; A is H or a covalent bond; and t is an integer having a value of 0 or 1; with the proviso that when A is H, t is 0 and when A is a covalent bond, tis 1. When A is a covalent bond and t is 1, the glycyl lysine derivative moieties may be attached to the benzene linking group in the ortho, meta or para position.
Preferably, the substituents X* and X> are attached to the phenyl ring of the benzyl moiety in the 4- position relative to the benzylic CH, (i.e. para substituent). The preferred X* and X? groups are C, to C, perfluoroalkyl, most preferred is para-trifluoromethyl. The preferred R? and R? groups are hydrogen and methyl. The substituents X? and X® may be the same or different, and the ~ substituents R? and R? may also be the same or different.
A particularly active member of the family of compounds represented by Formula (II), wherein A is a covalent bond and t is 1, is the compound represented by Compound 1 below: 10° 0}
H NH 0
Anni] SO 0 H :
X | Te
F: 3 Fs (Compound 1) . :
The compounds of Formulas (I) and (II) may be synthesized from readily available materials in a moderate number of synthetic steps. For example, Scheme 1 shows the synthesis of Compound 1, and is illustrative of a general method of producing compounds of Formula (II) wherein A is covalent bond, R? and R? are the same and X* and X® are the same.
Scheme 1 further illustrates the synthesis of compounds of Formula (IT), wherein X? and X> are both para-trifiuoromethyl, and R? and R® are both either methyl or hydrogen.
Scheme 1.
[0]
HO soc _Ms 1. Disuccinimidyl © carbonate . HN o 2. N-g-BOC-lysine methyl T ester; 99% ’
Fa
Compound 2 Fa ) 1. HCI - dioxane
SE R—nH 0 2. BOC-Gly EDC! i _Me 96% (o] he .
Compound 3, R=BOC
HCl-dioxane 99%
CFs
Compound 4, R=H *HC
Isophthaloy! : dichloride 68% lo) rte ’ o)
An “vr ho _R
YT } Y
Compound 5, R=Me - O
CFs LIOH CF, 93%
Compound 1, R=H [**Cl-Compound 1 was prepared in 25% overall yield from BOC '*C}-Gly
In Scheme 1, p-trifluoromethyl benzyl alcohol was reacted with disuccinimidyl carbonate to form an activated ester intermediate, which, in turn, was reacted with N-e-BOC-lysine methyl ester to afford Compound 2 in 99% yield. Hydrolysis of the BOC protecting group and subsequent coupling with
BOC-glycine afforded Compound 3 in 96% yield. Acid hydrolysis of the BOC protecting group of Compound 3 afforded Compound 4 in 99% yield. Coupling of two equivalents of Compound 4 with isophthaloyl dichloride provided a 68 % yield of Compound 5, corresponding to Formula (IT) where Rand R® are methyl,
X? and X? are p-triflucromethyl, and A is a covalent bond. Hydrolysis of
Compound 5 with lithium hydroxide produced a 93% yield of Compound 1.
The syntheses of compounds of Formulas (I) and (I) that are analogs of Compound 1 having other R and X substituents may be achieved by modifications of Scheme 1 that will be readily apparent to those of skill in the synthetic chemical arts. Use of a benzyl alcohol with a substituent other than p- trifluoromethyl (e.g. halo, nitro or other C, to C, perfluoroalkyl groups in either the ortho, meta or para position relative to the benzyl CH,) or use of a protected lysine ester having an ester group other than methyl, will afford other compounds of Formula (II).
The synthesis of compounds of Formula (I) having Z groups other than 1,3-phenyl is achieved, for example, by the substitution of other diacid dichlorides, such as bischlorocarbonylacetylene, fumaryl dichloride, phthaloyl dichloride, for isophthaloyl dichloride in Scheme 1. Alternativelyl, the corresponding acids may be utilized in the place of the acid chlorides, and : coupling of the acids to the appropriate amines may be achieved via standard peptide coupling techniques well known in the art. Those of skill in the art will readily recognize other chemical material substitutions that can be made in the synthetic methods illustrated in Schemes 1 and 2 to synthesize other members of the group of compounds represented in Formulas (I) and (II). The synthesis of related compounds and useful chemical strategies adaptable to the synthesis of compounds of Formulas (I) and (II) are described by Boger et al. in J. Am.
Chem. Soc. 123, 1280-1288 (2001).
Compounds of Formula (II) wherein A is a covalent bond, tis 1 and either R? is different from R3, or X? is different from X>, or both R? / R® and
X?/ X2 differ, can also be synthesized by modifications of the method presented in Scheme 1, which will be readily apparent to those of skill in the art. For example, one equivalent of Compound 4 can be reacted with the isophthaloyl dichloride, or any suitable isophthalic halide or active ester, and the second activated acid group can be sequentially reacted with an analog of Compound 4 having either a different X group, or a different R group, or both. Likewise, two analogs of Compound 4 having either a different X groups, or a different R group, or both can be sequentially reacted with isophthaloyl dichloride or an equivalent activated isophthalate to provide additional analogs of Compound 1 with dissimilar X and R groups.
The synthesis of compounds of Formula (II), wherein A is hydrogen and t is O is illustrated by the synthesis of Compounds 6 and 7 in
Scheme 2, below: .
Scheme 2 o
Benzoyl oh. 0
Compound 4 __""% aot 90% 0 HN Lr CFs
Compound 6, R=Me I
Compound 7, R=H : [e]
Compound 4 ~~ Diglycolic A y S -_ lo] N _Me % L TN Yosh
Compound 8 Y
In Scheme 2, Compound 4 of Scheme 1 is reacted with benzoyl . chloride to afford Compound 6 (R= methyl;X? = p-trifluoromethyl) in 90 % yield. Hydrolysis of the ester group of 6 with lithium hydroxide afforded
Compound 7 ( R?= H, X?* = p-triflucromethyl) in 88% yield.
Benzoylation of analogs of Compound 4 with different R groups (e.g. other C,-C, alkyl groups) and /or with different X substituents on the benzyl group lead to other compounds of Formula (IT) having A = Hand t = 0.
Also illustrated in Scheme 2 is the synthesis of Compound 8, an inactive analog of Compounds 6 and 7 wherein the benzoyl moiety attached to the glycine unit of Formula (II) is replaced by a diglycolic amide group. Compound 9 is obtained in 77% yield by coupling of Compound 4 to diglycolic acid.
Scheme 3, below, illustrates the synthesis of Compound 12, an inactive analog of Compound 1, in which the p-trifluoromethylbenzyloxycarbonyl group of Formula (II) is replaced by a benzoyl amide. :
Scheme 3. 0] | : sooth ~~ _Me
N-g-BOC-lysine methyl PhCOCI, 78% ah ester —_— 0
Compound 9
BOC-NH H 0 , N _Me . 1. HCI - dioxane Ne Po 1. HCldioxane — o HN. o AE ——— 2. BOC-Gly EDCI 2. Isophthaloyi 950% dichloride
Compound 10 62%
[0]
NH o)
PN aoe N R a NH le} Lo} HN. o.
Compound 11, R=Me
LiOH 73%
Compound 12, R=H
In a method aspect of the present invention, pharmaceutical preparations of compounds of Formulas (I) and (II) can be prepared by formulating the compound in a pharmaceutically acceptable carrier matrix. The pharmaceutical compositions comprising the active compounds of Formulas (I) and (II) are administered to a host with a tumor to reduce or eliminate tumor growth. The active compounds can be administered parenterally by injection, or by gradual infusion over time. Although the tissue to be treated is most often treated by intraperitoneal or subcutaneous administration, the active compounds can also be administered intraocularly, intravenously, intramuscularly, intrasynovially, intracavity, or transdermally, and can be delivered by peristaltic means as well.
The term "administration" of the inventive compound or composition, as used herein, refers to systemic use as when taken orally, parenterally, by inhalation spray, by nasal, rectal or buccal routes, or topically in dosage form unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants and vehicles as desired. The term "parenteral" as used herein includes intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion techniques.
By "pharmaceutically acceptable” it is meant those salts, amides and esters which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio, effective for their intended use in the treatment of : tumors and angiogenic-related disorders.
Pharmaceutically acceptable salts are well known in the art. For example, S. M ‘Berge, et al. describe pharmaceutically acceptable salts in detail in
J. Pharmaceutical Sciences, 66: 1-19 (1977). Representative acid addition salts include hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, toluenesulfonate, methanesulfonate, citrate, maleate, fumarate, succinate, tartrate, ascorbate, glucoheptonate, lactobionate, lauryl sulfate salts and the like.
Representative alkali or alkaline earth metal salts include sodium, calcium, potassium, magnesium salts and the like.
As used herein, the term "pharmaceutically acceptable carriers” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of the materials that can serve as pharmaceutically acceptable carriers are sugars, such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in pharmaceutical formulations.
Wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgement of the formulator. Examples of pharmaceutically acceptable antioxidants include water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, and the like; oil soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol and the like; and the metal chelating agents such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like.
By a "therapeutically effective amount” of the inventive agent or compound is meant a sufficient amount of the compound to treat tumors and angiogenic-related disorders at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgement. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidently with the specific compound employed; and like factors well known in the medical arts.
This invention also provides pharmaceutical compositions in unit dosage forms, comprising a therapeutically effective amount of a compound (or compounds) of this invention in combination with a conventional pharmaceutical carrier. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. : In addition, fatty acids such as oleic acid are used in the preparation of injectables. The injectable formulation can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
In order to prolong the effect of a drug, it is often desirable to slow the absorption of a drug from subcutaneous or intramuscular injection. The most common way to accomplish this is to inject a suspension of crystalline or amorphous material with poor water solubility The rate of absorption of the drug becomes dependent on the rate of dissolution of the drug which is, in turn, . dependent on the physical state of the drug, for example, the crystal size and the crystalline form. Another approach to delaying absorption of a drug is to administer the drug as a solution or suspension in oil. Injectable depot forms can also be made by forming microcapsule matrices of drugs and biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the composition of the polymer, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly-orthoesters and polyanhydrides. The depot injectables can also be made by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycol which are solid -at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders, prills and granules. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Tablets and pills can additionally be prepared with enteric coatings and other release-controlling coatings. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
Liquid dosage forms for oral administration may include pharmaceutically acceptable lo emulsions, microemulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as water. Such compositions may also comprise adjuvants, such as wetting agents; emulsifying and suspending agents; sweetening, flavoring and perfuming agents. If desired, the compounds of the present invention can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can dissolve in sterile water, or some other sterile injectable medium immediately before use. The active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and - 10 other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferably, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Dosage forms for topical or transdermal administration of a compound of this invention : further include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
Ophthalmic formulations, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention. The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin.
The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel. :
The compositions containing the active compounds are administered in a manner compatible with the dosage formulation and in a therapeutically effective amount. The quantity to be administered and the timing of administration depend on the host to be treated, capacity of the host’s system to utilize the active ingredient, and degree of therapeutic effect desired. Precise amounts of the active ingredient required to be administered depend on the judgment of the practitioner, and are peculiar to each individual.
Suitable dosage ranges for systemic application are disclosed herein and depend on the route of administration. Suitable regimes for administration are also variable, but are typified by an initial administration, followed by repeated doses at one or more predetermined intervals by a subsequent injection or other route of administration.
The present invention also provides a pharmaceutical composition useful for practicing the therapeutic methods described herein. The compositions contain an active compound described hereinabove, together with a pharmaceutically acceptable carrier.
Preparations for parental administration of the present compounds or compositions include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters : such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
Parental vehicles include sodium chloride solution, Ringer’s dextrose, dextrose and sodium chloride, lactated Ringer’s, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer’s dextrose), and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases, and the like.
Another aspect of the present invention provides a method for - inhibiting MMP? interaction with «8; and thus angiogenesis in a tumor tissue.
The inhibiting method comprises administering to the host a composition comprising an angiogenesis-inhibiting amount of a compound described hereinabove. MMP2 interaction with o,f is inhibited by contacting «,B, with a compound of the present invention. .
Angiogenesis is the formation of a neovascular network from pre- existing host vessels and is required for tumor growth beyond 1-2 mm?®. For the purpose of the present invention, angiogenesis is inhibited as long as angiogenesis and the disease symptoms mediated by angiogenesis are ameliorated.
The dosage ranges for the administration to a host of the active compound depend upon the particular active compound and its potency to a particular tumor or integrin. One skilled in the art can readily determine the proper dosage for a particular active compound without undue experimentation.
The host can be any mammal. The dosage should be large enough to produce the desired therapeutic effect in which angiogenesis and the disease symptoms mediated by angiogenesis are ameliorated, and is usually an amount sufficient to maintain a plasma level of the active compound in the range of about 0.01 to about 100 micromolar (uM), preferably about 0.2 to about 20 uM, more preferably about 1 to about 10 uM. The dosage should not be so large as to cause adverse side effects, however. The dosage per kilogram (kg) of body weight can vary from 1 to 20 mg per dose, in one or more dose administrations daily, for one or several days or indefinitely. : For inhibition of angiogenesis, the therapeutically effective amount is an amount of active compound sufficient to produce a measurable inhibition of angiogenesis in the tissue being treated, i.e., an angiogenesis-inhibiting amount or an MMP2 - a J, interaction inhibiting amount. Inhibition of angiogenesis can be measured in situ by immunohistochemistry, as described herein, or by other methods known to one skilled in the art.
The present invention additionally provides pharmaceutical compositions useful for practicing the therapeutic methods described herein. The compositions contain an active compound defined hereinabove together pharmaceutically acceptable carrier.
The present invention also provides a method of inducing apoptosis in tumor cells. This method comprises administering to the host a therapeutically effective amount of an active compound sufficient to initiate tumor cell apoptosis.
For the purpose of the present invention, tumor cell apoptosis is induced if an increased tumor cell apoptosis is observed in the target tumor being treated. Tumor cell apoptosis can be measured by methods described herein or commonly known in the art.
The following non-limiting examples are provided to illustrate various aspects of the present invention.
Materials and Methods : :
Antibodies Cells and Reagents. CS-1 hamster melanoma cells and
CS-1 cells transfected with the human f;-integrin subunit (§,CS-1 cells) were described previously (Cell, 85, 683-93 (1996); Cell, 92, 391-400 (1998)). The horseradish peroxidase (HRP)-conjugated monoclonal antibodies anti-biotin mAb
BN-34 and anti-actin mAb AC-40 were obtained from Sigma (St. Louis, MO).
Anti-von Willebrand Factor (vWF) polyclonal antibodies (pAb) were obtained from DAKO (Glostrup, Denmark). The cyclic peptides cRGDfV and cRADfV and integrin-a, 3; were generously provided by Merck KGaA (Darmstadt,
Germany). Purified proMMP2 and integrin-c. 3; were provided by Chemicon
International (Temecula, CA). Purified active MMP2 was obtained from : Calbiochem (La Jolla, CA). Basic fibroblast growth factor (bFGF) was kindly provided by Scios (Mountain View, CA).
Synthesis [**C]-Compounds. [“C]-labeled Compound 1 was synthesized by a slight modification of the sequence described earlier for the unlabeled material (Scheme 1), but utilizing N-BOC-[1-"*C]-glycine (55 mCi/mmol, American Radiolabeled Chemicals, St. Louis, MO). The overall yield of [**C}-Compound 1 was 25% for the four step sequence.
Example 1. Solid Phase Integrin Binding Assays.
Purified integrins were adsorbed overnight onto microtiter wells (1- ug/ml, 50 pg/well) prior to blocking with Caseinblocker (Pierce, Rockford, IL).
Purified biotinylated MMP2 (bMMP2, 3-5 nM) in binding buffer (50 mM Tris, pH 5 8, 150 mM NaCl, 1 mM MgCl,, 0.5 mM MnCl,) was added to the wells in the presence or absence of Compound 1, Compound 12, cyclic RGD or RAD peptides, or buffer vehicle alone. Control wells received no integrin. Biotinylated vitronectin (bVN, 1 pg/ml) was used as a reference. Bound protein was detected with HRP-anti-biotin mAb and quantitated at 450 nm with 3,3',5,5'- tetramethylbenzidine solution (TMB; a substrate for the peroxidase) (BioRad,
Hercules, CA).
For the assessment of direct integrin binding by Compound 1, 3, and asB; (10 pg/ml, 50 ul/well) were coated onto Immulon-4 microtiter wells (Dynatech Laboratories, Chantilly, VA), which were substantially blocked and incubated with titration of {'*C]-Compound 1 prior to the addition of 150 ul of binding buffer containing 0.1% Tween-20 and aspiration of all liquid. Dried wells were separated and immersed in BetaMax liquid scintillation cocktail (ICN
Biochemicals, Costa Mesa, CA) for quantitation. From this binding curve a subsaturating concentration (3 uM) of ["*C]-Compound 1 was examined in the presence and absence of a 25-fold molar excess (75 ul) of unlabeled Compound 1 or Compound 12, or 100 pM cyclic RGD or RAD peptide. Control was bVN, used and detected as described above. : Example 2. MMP2 Cell-Binding and [*H]-Collagen IV Degradation Assays.
CS-1 cells or B,CS-1 cells were incubated in adhesion buffer fibroblast basal medium (FBM) supplemented with 0.5% bovine serum albumin (BSA), 0.4 mM MnCl, and 10 pg/ml aprotinin) containing either 4 nM purified active MMP?2 alone, or in combination with 10 pM Compound 1 or Compound 12 for 45 minutes at 37 °C prior to washing and addition to the [’H]-collagen IV- coated wells. Wells had been coated overnight with 50 ul of 0.414 mCi/ml [*H]- collagen IV (ICN Biochemicals, Costa Mesa, CA) and washed extensively until the radioactivity in the recovered wash solution reached background. Alternatively,
© -25- cells were treated as above in the absence of MMP2, or the MMP2 solutions were added directly to the wells without cells, as controls. Collagen IV degradation was quantitated by measuring the radioactivity released into the 50 pl of culture medium as determined in a liquid scintillation counter. For the assessment of biotinylated
MMP2 binding to CS-1 cells, cells were suspended in adhesion buffer and incubated with 12 nM bMMP2 for 45 minutes at 37 °C in the presence or absence of 10 uM Compound 1 or Compound 12. Cells were subsequently washed before lysis and processing for SDS-PAGE and immunoblotting with an anti-biotin mAb. 100 Example 3. Chick Chorioallontoic Membrane (CAM) Angiogenesis Assay.
Angiogenesis was assessed essentially as described previously (Cell, 85, 683-93 (1996); Cell, 92, 391-400 (1998)). After stimulation with 3 pg/ml of basic fibroblast growth factor (bFGF), 10 day chick embryo CAMs were treated with 20 pl of 3uM Compound 1 or Compound 12. Three days after induction, the
CAMs were quantitated in a blind evaluation. CAMs from each group were pooled, minced, and extracted with 50 mM Tris, 150 nM NaCl, 0.1 % Triton X-100 containing COMPLETE-brand protease inhibitor cocktail without EDTA (Boehringer, Mannheim, Germany) prior to analysis by zymography.
Example 4. SDS-PAGE, Immunoblotting and Zymography.
Immunoblotting. Equal quantities of protein were separated by
SDS-PAGE under reducing conditions and electroblotted to an Immobilon-P membrane (Millipore, Bedford, MD). The membrane was blocked and immobilized proteins were detected by incubation with an anti gen-specific primary antibody, followed by an HRP-conjugated secondary antibody as required. Bands were visualized the chemiluminescent substrate PS-3 (Lumigen, Inc., Southfield,
MD).
Zymography. Chick CAM lysates were prepared as described above and equal quantities of protein were separated in the absence of reducing agents or boiling on polyacrylamide gels embedded with 0.2% gelatin. The gels were washed with 2% Triton X-100, followed by extensive washing with water prior to overnight incubation at 37 °C in collagenase buffer (50 mM Tris 7.4, 200 mM NaCl 10 mM CaCl2). Gelatinolytic activity was visualized by staining the gels with 0.5% Coomassie blue.
Example 5. Tumor Growth Assay.
Primary tumors were grown on CAMs of 9-day embryos by implantation 5 x 10° CS-1 cells and incubation for 7 days. At this point, 50 mg sections of these tumors were subcultured onto fresh 9-day CAMs and allowed to implant for 24 hours before a single intravenous (IV) injection with 100 pi of 100 uM of test compounds in Hank’sBalanced Saline Solution (HBSS). Buffer alone was used as control. Tumors were incubated for a total of 10 days, harvested and trimmed free of excess stromal tissue before determining wet weight and processing for histology.
Example 6. Immunofluorescence Assays
Snap-frozen CS-1 tumor sections were fixed with 4% paraformaldehyde and permeablized with 0.1% Triton X-100. Sections were blocked with 5% bovine serum albumin (BSA) in phosphate buffered saline (PBS) prior to staining with an anti-vWF pAb and visualization with an Alexa 568- conjugated anti-rabbit secondary antibody. Samples were analyzed on a MRC1024 confocal microscope (BioRad, Hercules, CA). Blood vessel density was quantitated with a 20X objective on four fields per section and four tumors per condition.
Example 7. (S)-Methyl 6-(({tert-butyloxy)carbonyl)amino)-2-((4-trifluoromethyl)- benzyloxycarbonylhexanoate (2).
A solution of N,N’-disuccinimidyl carbonate (5.38 g, 21 mmol) in acetonitrile (150 mL) was treated with 4-(trifluoromethyl)benzyl alcohol (2.87 mL, 21 mmol) and Et;N (5.8 mL, 42 mmol) and stirred at 25 °C. After 3 h, the ' reaction mixture was added to a flask containing N-e-BOC-lysine methyl ester (4.2 g, 14 mmol) in acetonitrile and stirred for an additional 3 h. The solvent was evaporated and the residue dissolved in CH,Cl, (250 mL) and washed with 10% aqueous HCI (2 x 200 mL) and saturated aqueous NaHCO,, (200 mL).
Co =27-
Flash chromatography (SiO, 3:1 CH,Cl,/EtOAc) provided 6.4 g (99%) of 2 as a pale yellow oil: [¢],>-8.9 (c 5.6, CH,;OH); '"H NMR (CDCl,;, 400 MHz) 8 7.57 (d, /=8.1 Hz, 2H), 7.39 (d, J=8.1 Hz, 2H), 5.70 (d, J=7.9 Hz, 1H), 5.13 (m, 2H), 4.71 (m, 1H), 4.28 (m, 1H), 3.67 (s, 3H), 3.03 (m, 2H), 1.78 (m, 1H), 1.64, (m, 1H) 1.46-1.32 (m, 4H) 1.35 (s, 9H); *C NMR (CDCl, 100 MHz) 8 172.9, 156.2, 155.8, 140.4, 130.1 (q, /=32.0 Hz), 127.8, 125.3, 122.9 (q,
J=270.0 Hz), 79.05, 65.8, 53.7, 52.3, 39.8, 31.7, 29.5, 28.4, 22.2; IR (film)
U,, 3357, 2952, 1790, 1745, 1524 cm; FABHRMS (NBA-Nal) m/z 463.2044
M + H*, C,H, F;N,0, requires 463.2056).
Example 8. (S)-Methyl 6-[2-(((tert-buityloxy)carbonyl)amino)acetamido}-2-[(4- trifluoromethyl)benzyloxycarbonyllhexanoate (3).
A solution of Compound 2 (2.7 g, 5.8 mmol) in CHCl, (3 mL) ) was treated with 4N HCl-dioxane (10 mL) and stirred for 20 min at 25 °C.
Solvent and excess acid were removed under reduced pressure, and the crude hydrochloride salt was dissolved in DMF (50 mL), treated with N-((tert- butyloxy)carbonyl)glycine (1.0 g, 5.8 mmol), 1-(3-(dimethylamino)propyl)-3- ethylcarbodiimide hydrochloride (EDCI) (1.2 g, 6.4 mmol) and i-Pr,NEt (2.0 mL, 11.6 mmol) and stirred for 12 h at 25 °C. The reaction mixture was diluted with EtOAc (400 mL) and washed with 10% aqueous HCI (3 x 250 mL) and saturated aqueous NaHCO, (250 mL), dried (Na,SO,) and evaporated to provide 2.89 g (96%) of Compound 3 as a white foamy solid: [12 -10.4 (c 2.5,
CH,0H); 'H NMR (CDCl,, 400 MHz) & 7.59 (m, 2H), 7.45 (m, 2H), 6.19 (m, 1H), 5.51 (m, 1H), 5.13 (m, 2H), 4.32 (m, 2H), 3.74 (s, 3H), 3.73 (m, 2H), 3.26 (m, 2H), 1.81-1.39 (m, 6H) 1.44 (s, 9H); “C NMR (CD,0D, 100 MHz) 174.5, 172, 158.2, 158.1, 142.7, 130.8 (gq, /=31.8 Hz), 128.8, 126.3, 125.5 (gq,
J=269.7 Hz), 80.5, 66.5, 55.3, 52.7, 44.6, 39.8, 32.1, 29.8, 24.0; IR (film)
VU, 3320, 2932, 1721, 1692, 1326 cm; FABHRMS (NBA-Csl) m/z 652.1234
M + Cs*, C,H, F;N,0, requires 652.1247).
Example 9. 6-[2-(amino)acetamido]-2-[(4-trifluoromethyl)-benzyloxycarbonyl] : hexanoate hydrochloride (4).
A solution of Compound 3 (350 mg) in CH,Cl, (2mL) was treated with 4 N HCl-dioxane (5.0 mL) and stirred at 25 °C. After 0.5 h, solvent and excess acid were removed under reduced pressure, providing 300 mg (99%) of
Compound 4 as a pale yellow oil: []p® -10.4 (c 3.0, CH,OH); 'H NMR (CD,0D, 400 MHz) 6 7.65 (d, J=8.2 Hz, 2H), 5.18 (d, J=13.3 Hz, 1H), 5.16 (d, J=13.3 Hz, 1H), 4.16 (m, 1H), 3.70 (s, 3H), 3.65 (s, 2H), 3.21 (t, J=7.1
Hz, 2H), 1.84 (m, 1H), 1.68 (m, 1H), 1.54 (m, 2H), 1.42 (m, 2H); *C NMR (CD,0D, 100 MHz) 6174.5, 167.1, 158.2, 142.8, 130.8 (q, J=31.8 Hz), 128.8, 126.3, 125.5 (q, /=270.1 Hz), 66.5, 55.4, 52.7, 41.5, 40.2, 32.1, 29.6, 24.1; IR (film) v,,, 3317, 2954, 1718, 1684, 1530, 1327 cm; MALDIFTMS (DHB) m/z 442.1586 (M + Na*,
C,sH, F;N;0; requires 442.1566).
Example 10. N.N'-Bis[(5-(S)~(methoxycarbonyl)-5[((4-trifluoromethyl)-benzyl oxycarbonyhamino]pentyl)carboxamidomethyl]benzene-1,3dicarboxamide (5)
A solution of Compound 4 (2.05 g, 4.0 mmol) in CH,Cl, (3.0 mL) was treated with 4 N HCl-dioxane (10.0 mL) and stirred for 20 min at 25 °C.
Solvent and excess acid were removed under reduced pressure, and the crude hydrochloride salt was suspended in DMF (40 mL) and treated with isophthaloy] dichloride (400 mg, 2.0 mmol), and i-Pr,NEt (1.4 mL, 8.0 mmol) and stirred for 1h at 25 °C. The reaction mixture was diluted with EtOAc (400 mL) and } washed with 10% aqueous HCI (3 x 200 mL) and 5% aqueous Na,CO; (200 mL), dried (Na,SO,), and evaporated. Flash chromatography (SiO,, 1:4.5:4.5
MeOH/CH,Cl,/EtOAc) provided 1.30 g (68%) of Compound 5 as a yellow powder: [a], -6.4 (c 2.1, CH,0H): '"H NMR (CDCl,, 400 MHz) & 8.29 (m, 2H), 8.11 (m, 2H), 7.87 (m, 4H), 7.53 (m, 2H), 7.39 (m, 2H), 6.88 (m, 2H), 5.94 (m, 2H), 5.08 (m, 4H), 4.30 (m, 2H), 4.01 (m, 4H), 3.70 (s, 6H), 3.23 (m, 4H), 1.77 (m, 2H), 1.67 (m, 2H), 1.51 (m, 4H), 1.37 (m, 4H); °C NMR (CD,0D, 100 MHz) 6 174.6, 171.5, 169.3, 158.3, 142.7, 135.3, 131.6, 30.8 (q,
J=32.2), 129.8, 128.8, 127.6, 126.3, 125.5 (q. J=269.2), 66.5, 55.4, 52.7,
44.1, 40.0, 32.1, 29.8, 24.1; IR (film) v,,, 3305, 2951, 1716, 1651, 1538 cm;
FABHRMS (NBA-CsI) m/z 1101.2398 M +Cs™*, CH, F,N,O,, requires 1101.2445).
Example 11. N.N'-Bis-[(5-(S)-carboxy-5-[((4-trifluoromethyl)benzyloxycarbonyl) amino]-pentyl)carboxamidomethylbenzene-1,3-dicarboxamide (1).
A solution of Compound 5 (0.95 g. 0.98 mmol) in THF-MeOH (8.0 mL, 3:1) was treated with LiOHH,0 (165 mg, 3.9 mmol) in H,O (2.0 mL) and stirred at 0°C. After 2 h, the reaction was quenched by the addition of 10% aqueous HCI (20 mL) and the mixture was extracted with EtOAc (3 x 50 mL).
The organic layers were combined and washed with saturated aqueous NaCl (50 mL), dried (Na,SO,) and evaporated to provide 0.86 g (93%) of Compound 1 as a white powder: [a]5” -0.6 (c 3.2, CH,0H); 'H NMR (CD,0D, 400 MHz) & 8.40 (m, 1H, 8.03 (dd, /=1.8, 7.8 Hz, 2H, 7.62 (d, J=8.1 Hz, 4H), 7.53 (t,
J=6.1 Hz, 1H), 7.51 (d, J=8.1 Hz, 4H, 5.16 (d., J.=13.3 Hz, 2H), 5.13 (d,
J=13.3 Hz, 2H), 4.12 (m, 2H), 4.00 (s, 4H), 3.22 (t, J=6.6 Hz, 4H), 1.85 (m, 2H), 1.70 (m, 2H), 1.55 (m, 4H, 1.37 (m, 4H); ’C NMR (CD,0D, 100 MHz) & 175.9, 171.6, 169.4, 158.4, 135.4, 131.6, 30.5 (q, J=31.8), 129.8, 128.8, 127.7, 126.3, 125.6 (q. J=268.7); 66.5, 53.3, 44.2, 40.1, 32.2, 29.8, 24.2; IR (film) v,,, 3334, 2933, 1718, 1646, 1631, 1528 cm; MALDIFTMS (DHB) m/z 963.2953 (M+Na*,C,H,F,N,O,, requires 963.2976).
Example 12. [*C]-Compound (1)
A solution of [1-"*C]-glycine (American Radiolabeled Chemicals, "25 1.0 mCi, 55 mCi/mmol, 0.018 mmol) in 0.1 N HCI was transferred to a 4 mL vial and the solvent was removed under a stream of N,. The resulting residue was treated with a solution of NaHCO;, (4.6 mg, 0.054 mmol) in H,O (0.25 mL) and a solution of di-terz-butyl dicarbonate (10.5 mL, 0.045 mmol) in THF (0.25 mL) and stirred at 25 °C. After 12 h the solution had become homogeneous and was diluted with H,O (1.0 mL) and washed with diethyl ether (2 x 1.0 mL). The aqueous solution was then acidified by the addition of 10% aqueous HCI (0.5 mL) and extracted with ethyl acetate (4 x 1.0 mL). The combined extracts were dried (Na,SO,) and evaporated under a stream of N, to provide 2.9 mg (92%) of [1-#C]J-N-BOC-glycine as a white film.
A solution of Compound 2 (50 mg, 0.11 mmol) in CH,Cl,(1 mL) was treated with 4 N HCl-dioxane (1 mL) and stirred for 1 h at 25 °C. The reaction mixture was diluted with ethyl acetate (25 mL) and washed with 10% aqueous Na,CO; (25 mL) and saturated aqueous NaCl (25 mL) dried (Na,SO,) ~and evaporated to provide the deprotected lysine as a colorless film. A portion of this free amine (4.5 mg, 0.013 mmol) in DMF (0.2 mL) was added to a 4 mL vial containing [1-'“C]-N-BOC-glycine (1.5 mg, 0.0085 mmol) and treated with i-
Pr,NEt (2 mL) and a solution of EDCI (5.0 mg, 0.026 mmol) in methylene chloride (0.1 mL) and stirred for 3 h at 25 °C. The reaction mixture was diluted with EtOAc (2.0 mL) washed with 10% hydrochloric acid (3 x1.0 mL), saturated aqueous Na,CO, (1.0 mL) and saturated aqueous NaCl (1.0 mL), and evaporated.
Preparative thin layer chromatography (PTLC) (SiO,, EtOAc/CHCI, 1:1) provided 1.8 mg (41%) of [*“C]-Compound 3 as a white film.
A 4 mL vial containing [*C]-Compound 3 (1.8 mg, 3.5 mmol) was treated with 4 N HCl-dioxane (0.25 mL) and the reaction stirred for 0.5 h at 25 °C. Solvent and excess acid were evaporated under a stream of N, and the resulting crude hydrochloride salt was treated with isophthaloyl dichloride (355 mg 0.0018 mmol) in CH,Cl, (0.1 mL), and i-Pr,NEt (2.4 mL, 0.014 mmol) in
CH,C1, (0.05 mL). After 3 h at 25 °C, the reaction mixture was directly purified by PTLC (Si0,, MeOH/CHCI,/EtOAc 1:9:9) to provide 1.2 mg (71%) of [“C]-
Compound 5.
A solution of [“C]-Compound 5 (1.2 mg) in THF-MeOH (0.2 mL, 1:1) was treated with a solution of LiOH+H,O (0.4 mg) in H,0 (0.05 mL) at 0 °C and stirred for 1 H. The reaction mixture was diluted with methanol (1.0 mL) and treated with Dowex 50WX-8 acid cation exchange resin (200 mg) and stirred for 1 min. The mixture was then filtered through cotton wool and the filtrate evaporated to provide 1.1 mg (94%) of ["*C]-Compound 1 relative activity approximately 110 mCi/mmol. This compound and all its synthetic intermediates were identical by thin layer chromatography (TLC) comparison to the corresponding unlabeled material.
Example 13. (S)-Methyl 6-[2-(benzoylamino)acetamido]-2-{(4-trifluoromethyl)- benzyloxycarbonyDhexanoate (6).
A solution of Compound 3 (44 mg, 0.085 mmol) in CH,Cl, (1.0 mL) was treated with 4 N HCl-dioxane (1.0 mL) and stirred for 1 h at 25°C.
Solvent and excess acid were removed under a stream of N,, and the crude by hydrochloride salt was suspended in CH,Cl, (0.8 mL) and treated with i-Pr,NEt (30 pL, 017 mmol) and benzoyl chloride (11 pL, 0.094 mmol) and stirred for 25°C. After 2 h the reaction mixture was directly purified by flash chromatography (SiO,, 1:9:9 MeOH/CH,CL,/EtOAc) to afford 40 mg (90%) of
Compound 6 as a white powder: [e],>-2.7 (c 0.70, CHCl); 'H NMR (CD,0D, 400 MHz) & 7.86 (m, 2H), 7.64 (m, 2H), 7.53 (m, 3H), 7.45 (m, 2H), 5.16 (m, 2H), 5.16 (dd, J = 7.3, 3.8 Hz, 1H), 3.69 (s, 3H), 3.21 (t, J = 5.6 Hz, 2H), 1.81 (m, 1H), 1.69 (m, 1H), 1.53 (m 2H), 1.42 (m, 2H); *C NMR (CDC1,, 100
MHz) 8 172.8, 169.5, 168.4, 156.3, 142.3, 132.9, 131.4, 129.4 (q, J = 32.2
Hz), 128.0, 127.1, 126.7, 126.3 (q, J - 269.0 Hz), 124.8, 65.1, 53.6, 51.6, 42.6, 38.4, 30.6, 28.1, 22.2; IR (film) v,,,, 3303, 2923, 1713, 1651, 1533 cm’;
FABHRMS (NBA-Csl) m/z 656.0961 (M + Cs, C,sH,sF;N;0,4 requires 656.0985).
Example 14. (S)-6-[2-(Benzoylamino)acetamido]-2-(4-trifluoromethyl)- : benzyloxycarbonyl]hexanoic acid (7).
A solution of Compound 6 (17 mg, 0.032 mmol) in THF-MeOH (0.4 mL, 3:1) was treated with LiOH*H,0 (2.0 mg, 0.49 mmol) dissolved in
H,0 (0.1 mL), and stirred for 2 h at 0°C. The reaction mixture was quenched by the addition of concentrated aqueous HCI (5 pL), diluted with EtOAc (30 mL) and washed with water (2 x 15 mL). Drying (Na,SO,) and evaporation provided 14.5 mg (88%) of Compound 7 as a white powder: [«],® + 2.2 (c 0.6, CH,0H); 'H NMR (CD,0D, 400MHz) & 7.86 (d, J = 7.2 Hz, 2H), 7.62 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 8.2 Hz, 2H), 7.53 (m, 1H), 7.43 (m, 2H), 5.17 (d, J = 13.2
Hz, 1H), 5.14 (d, J - 13.2 Hz, 1HO0, 4.14 (m, 1H), 4.04 (s, 2H), 3.25 (m, 2H), . 1.88 (m, 1H), 1.71 (m, 1H), 1.52 (m, 2H), 1.44 (m, 2H); *C NMR (CD,0D, 125 MHz) 6 175.9, 171.7, 170.5, 158.4, 142.9, 135.1, 132.9, 130.9 (q, J = 32.4 Hz), 129.5, 128.9, 128.5, 126.3, 125.7 (q, J - 269.0 Hz), 66.5, 55.4, 44.1, 40.1, 32.3, 29.9, 24.2; IR (film) v,_,, 3318, 2935, 1713, 1644, 1538, 1326 cm’;
MALDIFTMS m/z 532.1672 M + Na*, C,,H,,F;N,O; requires 532.1671).
Example 15. (S)-Methyl 6-[2-[(2-((carboxymethyl)methoxy)acetamido] acetamido]-2-[(4-trifluoromethyl)benzyloxycarbonyllhexanoate (8).
A solution of Compound 3 (57 mg, 0.11 mmol) in CH,CI, (1 mL) was treated with 4 N HCl-dioxane (2 mL) and stirred for 1 h at 25°C. Solvent and excess acid were removed under a stream of N,, and the residue was dissolved in DMF (1 mL) and treated with diglycolic acid (16 mg, 0,12 mmol),
EDCI (23 mg, 0.12 mmol) and i-Pr,NEt (42 pL, 0.24 mmol) and stirred at 25°C.
After 4h, the reaction mixture was poured into a separatory funnel containing
EtOAc (50 mL) and washed with 10% aqueous HCI (3 x 30 mL) and saturated aqueous NaCl (30 mL), dried (Na,SO,) and evaporated to afford 45 mg (77%) of monoacid Compound 8 as a white solid: [a]? - 7.5 (c 1.8, CH,0H); '"H NMR (CD,0D, 400 MHz) 6 7.65 (d, J = 5.2 Hz, 2H), 7.54 (d, J = 5.3 Hz, 2H), 5.18 d,J = 9.0Hz, 1H), 5.15 (d, J = 9.0 Hz, 1H), 4.42 (s, 2H), 4.16 (m, 1H), 4.11 (s, 2H), 3.87 (s, 2H), 3.70 (s, 3H), 3.20 (t, J = 4.5 Hz, 2H), 1.81 (m, 1H), 1.68 (m, 1H), 1.53 (m, 2H), 1.39 (m, 2H); *C NMR (CD,OD, 100 MHz) 6 174.5, 173.7, 172.5, 171.2, 158.2, 142.6, 130.9 (q, J = 33.2 Hz), 128.2, : 126.2, 125.4 (q, J = 270.1 Hz), 71.3, 69.0, 66.5, 55.3, 52.7, 42.9, 39.9, 32.0, 29.7, 23.9; IR (film) v,,,, 3315, 2931, 1725, 1661, 1538, 1326 cm’;
MALDIFTMS m/z 558.1686 (M + Na*, C,H,,F;N,O, requires 558.1673).
Example 16: (S)-Methyl 2-(benzoylamino)-6-(((tert-butyloxy)carbonyl)amino) hexanoate (9). . 30 A solution of N-e-BOC-lysine methyl ester hydrochloride (5.05 g, 17 mmol) in CH,Cl, (100 mL) was treated with benzoyl chloride (2.0 mL, 17 mmol) and i-Pr,NEt (5.9 mL, 34 mmol) and stirred at 25°C. After 1 h the reaction mixture was washed with 10% aqueous HCI (100 mL), dried (Na,SO,) and evaporated to a white powder which was crystallized from CH,Cl,-hexanes to afford 4.8 g (78%) of Compound 9 as a white crystalline solid with mp 108- 109°C.; [a]p>-13.2 (c 5.8), CH,0H); 'H NMR (DMSO-d,, 400 MHz) 6 8.72 (d,
J = 7.4 Hz, 1H), 7.89 (m, 2H), 7.55 (m, 1H), 7.48 (m, 2H), 6.88 (t, J - 5.2 Hz, 1H), 4.42 (m, 1H), 3.64 (s, 3H), 2.93 (m, 2H), 1.81 (m, 2H), 1.41 (m, 4H), 1.37 (s, 9H); PC NMR (DMSO-d,, 100 MHz) 6 172.9, 166.7, 155.6, 133.8, 131.5, 128.3, 127.6, 77.4, 52.8, 51.9, 40.8, 30.2, 29.2, 28.3, 23.2; IR (film)
Vax 3335, 2933, 1740, 1690, 1647, 1534 cm™; MALDIFTMS (DHB) m/z 387.1895 (M + Na*, C,,H,;N,0O; requires 387.1890).
Example 17. (S)-Methyl 2-(benzoylamino)-6-[2-(((tert-butyloxy)carbonyl)amino}]- acetamido)hexanoate (10). .
A solution of Compound 9 (4.4 g, 12.1 mmol) in CH,Cl (5.0 mL) was treated with 4 N HCl-dioxane (10.0 mL) and stirred for 3 h at 25°C.
Solvent and excess acid were removed under reduced pressure, and the residue was dissolved in DMF (150 mL) and treated with N-((tert- butyloxy)carbonyl)glycine (2.2 g, 12.1 mmol), PyBrOP (7.0 g, 15 mmol), and i-
Pr,NEt (8.4 mL, 48.4 mmol) and stirred at 25°C. After 12 h the reaction mixture was diluted with EtOAc (500 mL) and washed with 10% aqueous HCI (3 x 250 mL), 5% aqueous Na,CO, (250 mL) and saturated aqueous NaCl (250 mL), dried Na,SO,) and evaporated. Flash Chromatography (SiO,, EtOAc) provided 4.6 (90%) of Compound 10 as colorless oil: [&],>-10.3 (c 0.30,
CH,OH); 'H NMR (CDCl,, 400 MHz) 6 7.84 (m, 2H), 7.51 (m, 1H), 7.44 (m, 2H), 6.91 (d, J - 7.6 Hz, 1H), 6.35 (brt, J - 5.3 Hz, 1H), 5.22 (m, 1H), 4.76 (m, 1H), 3.76 (s, 3H), 3.70 (brt, J - 6.3 Hz, 4H), 3.26 (m, 2H), 1.95 (m, 1H), 1.84 (m, 1H), 1.57-1.30 (m, 4H), 1.41 (s, 9H); >*C NMR (CDC1,, 100 MHz) § 173.0, 169.7, 167.3, 156.5, 133.7, 131.8, 128.6, 127.2, 81.8, 52.5, 52.3, 44.3, 38.7, 32.0, 28.9, 28.3, 22.4; IR (film) v,,, 3318, 2954, 1718, 1647, 1535, 1491 cm’; MALDIFTMS m/z 444.2108 (M + Na*, C,,H;,N,0, requires 444.2110).
Example 18. N,N’-Bis[N-(-5-(S)-((benzoyl)amino)-5-(methoxycarbonylpentyl)- carboxamidomethyllbenzene-1.3-dicarboxamide (11).
A solution of Compound 10 (4.4 g, 10.4 mmol) in CH,Cl, (3 mL) was treated with 4.0 N HCl-dioxane (20 mL) and stirred for 1 H at 25°C.
Solvent and excess acid were removed under reduced pressure, and the residue dissolved in CH,Cl, (50 mL) and treated with Et,N (5.8 mL, 42 mmol) and isophthaloyl dichloride (1.06 g, 5.2 mmol) and stirred at 25°C. After 16 h, the reaction mixture was washed with 10% aqueous HCI (50 mL) and evaporated to a yellow oil. Flash chromatography (SiO,, 5:5:2 EtOAc/CH,Cl,/MeOH) afforded 2.5 g (62%) of Compound 11 as a white foamy solid: [«],*-8.0 (c 4.8, CH,OH); 'H NMR (CD,0D, 500 MHz) & 8.37 (s, 1H), 8.00 (m, 2H) 7.84 (m, 4H), 7.52 (m, 3H), 7.44 (m, 4H), 4.58 (m, 2H), 3.99 (two s, 4H); 3.72 (s, 6H), 3.22 (m, 4H), 1.99-1.83 (m, 4H), 1.59-1.40 (m, 8H); “C NMR (CD,0OD, 100 MHz) & 174.2, 171.5, 170.2, 169.0, 135.0, 134.8, 132.8, 131.5, 129.4, 128.4, 127.6, 54.3, 52.7,44.2, 40.1, 31.7, 29.8, 24.3; IR (film) v,_,, 3304, 2950, 1738, 1650, 1644, 1538 cm’; , MALDIFTMS m/z 795.3332 (M + Na*, C,oH,;N;O,, requires 795.3330).
Example 19. N,N’-Bis-[N-(-5-(S)-((benzoyl)amino)-5-(carboxy)pentyD- carboxamidomethyllbenzene-1,3-dicarboxamide (12).
A solution of Compound 11 (1.1 g, 1.4 mmol) in MeOH-THF (20 mL, 1:1) was treated with LiOH*H,O (240 mg, 5.7 mmol) dissolved in H,0 (10 mL) and stirred for 1 h at 0°C. After 1 h, the reaction solvent was evaporated : and the residue redissolved in H,O (20 mL) and cooled to 0°C. Concentrated aqueous HCI (0.47 mL, 5.7 mmol HCl) was added and the solid which precipitated was filtered and washed with water (50 mL to afford 0.78 g (73%) of
Compound 12 as a white powder: [0:],>-2.6 (c 0.35, CH,0H); 'H NMR (CD,0D, 400 MHZ) 6 8.38 (m, 1H), 8.02 (m, 2H), 7.84 (m, 4H), 7.55-7.48 (m, 3H), 7.42 (m, 4H), 4.56 (m, 2H), 4.00 and 3.99 (two s, 4H), 3.26 (m, 4H), 1.99-1.83 (m, 4H), 1.63-1.45 (m, 8H); *C NMR (CD,0D, 100 MHz) 3 175.5, 171.9, 170.4, 169.2, 135.0, 134.9, 132.8, 131.7, 129.8, 129.5, 128.5, 127.7, 54.4, 44.0, 40.2, 31.7, 29.6, 24.3; IR (film) v,,, 3280, 2923, 1718, 1641, 1536 cm’; MALDIFTMS (DHB) m/z 767.3005 (M + Na*, C,H, NO, requires 767.3017).
Results and Discussion | Compound 1 disrupts the RGD-independent interaction between "integrin «ff; and MMP2. The recent observation that the carboxy-terminal hemopexin-like domain of MMP2 can interfere with MMP2 binding to integrin «,B, and thus block angiogenesis prompted us to search for organic inhibitors of this interaction, which might be more amenable to therapeutic administration. To identify a specific inhibitor of the binding interaction between MMP2 and integrin a. f3,, solid phase receptor binding assays were performed with immobilized integrins and biotinylated MMP2. The binding of purified MMP2 was found to be entirely RGD-independent in this system, as evidenced by the lack of effect of cRGDfV on MMP2 binding to integrin o.,;, even though this peptide inhibited the interaction of a. 3; with its extracellular matrix ligand, vitronectin (VN; FIG. 2A). Importantly, the binding of MMP2, but not that of VN, was completely abrogated by Compound 1, demonstrating the specificity of Compound 1 for the interaction between MMP2 and «. f;. Furthermore, the binding between MMP2 and tissue inhibitor of metalloproteinase 2 (TIMP2) was not inhibited by
Compound 1, supporting the contention that the effect of this Compound 1 is restricted to the binding interaction between MMP?2 and integrin a. f3,, and demonstrating a distinction between the binding sites for the MMP2 PEX domain on TIMP? and integrin « f;. It is important to note that neither the control : compound nor the control peptide cRADSV interfered with MMP2 binding to integrin a 3; (FIG. 24).
Compound 1 binds directly to integrin «3; and not to MMP2. To further address the mechanism of action of Compound 1, additional solid phase receptor binding assays were performed with immobilized 3; and [**C]-labeled
Compound 1, or biotinylated VN as a control. As can be seen in Figure 2B,
Compound 1 bound directly to integrin af, in a solid phase receptor binding assay. This interaction was dose-dependent, saturable and specific, demonstrating minimal interaction of Compound 1 with the unrelated control
-36- © integrin 50, (FIG. 2B). Indeed, negligible binding to integrin a5B, was observed at higher concentrations of compound (data not shown). In addition, no binding of Compound 1 was observed when MMP2 was coated on the microtiter well (data not shown), suggesting that the effects observed in the MMP2/integrin o,f; binding assay are due to Compound I. binding to integrin «,,. Importantly, this interaction was inhibited by the presence of a 25-fold molar excess of unlabeled Compound 1, but not the related control compound 12 (FIG. 2C).
Furthermore, Compound 1 bound to integrin «,f; in an RGD-independent manner, as demonstrated by the inability of the cRGDfV peptide to inhibit the interaction of radiolabeled Compound 1 with integrin &., 85, even as cRGDfV completely abolished the binding of bVN to the immobilized integrin in the same system (FIG. 2D). The control peptide cRADfV is shown as a control for the specificity of the binding inhibition. Thus, Compound 1 binding to « p; exhibits comparable specificity, selectivity and lack of susceptibility to RGD inhibition to that of MMP2.
Interestingly, Compound 6, the compound of Formula (IT) where
A is hydrogen, n is 0, X* is p-trifluoromethyl and R! is methyl, was slightly less active than Compound 1 in the solid phase binding assay, whereas Compound 8, which lacks the phenyl group coupled to the glycine unit was inactive. This result demonstrates that the phenyl ring is an essential feature for inhibition activity for the inhibitor compounds of Formula (II), and further demonstrates that at least ope substituted glycyl lysine unit is necessary for the antiangiogenic activity of this class of inhibitors. : Cell-mediated collagen IV degradation via MMP?2 is blocked by
Compound 1. Prevention of MMP2 binding to integrin o,f; on melanoma cells was shown previously to inhibit cell-mediated collagen IV degradation in an c f;- dependent manner. Therefore, we assessed whether melanoma cells expressing or lacking a, could utilize activated MMP2 to degrade immobilized
PH]collagen IV. Importantly, neither cell produces detectable quantities of
MMP2 endogenously. While both cell types were capable of some level of basal collagen degradation, only the B;-transfected CS-1 cells were able to utilize the exogeneous MMP2, demonstrating significantly more release of substratum radioactivity into the culture medium after preincubation with purified MMP2 (FIG. 3A). This enhanced substrate degradation in response to treatment with
MMP2 was specifically abolished by inclusion of Compound 1, while Compound 12 had a negligible effect (FIG. 3A). Significantly, the effect of Compound 1 on cell-mediated collagen degradation was not due to a direct inhibition of MMP2 activity, as purified active MMP?2 in the absence of cells was still able to degrade the immobilized [*H]collagen IV irrespective of the presence or absence of either
Compound 1 or Compound 12. To demonstrate that the reduced cell-mediated collagen degradation observed in FIG. 3A was the result of inhibition of MMP2 interaction with integrin of; by Compound 1 on the cell surface, CS-1 cells and their «,f;-bearing counterpart were examined in a biotinylated MMP? binding assay. As expected, the 3;-negative CS-1 cells were capable of binding some level of MMP2, however their capacity to do so was not diminished by the presence of either compound (FIG. 3B). In contrast, 3,CS-1 cells bound significantly greater quantities of MMP2, and this enhanced MMP2 binding was specifically suppressed by Compound 1. In fact, when corrected for the loading of the lanes as demonstrated by staining with an anti-actin mAb, Compound 1 effectively reduced the binding of MMP2 to the $,CS-1 cells to the level observed in the absence a,b; (i.e. parental CS-1 cells)(FIG. 3B, lane 2).
Compound 1 disrupts ‘angiogenesis in vivo without suppressing
MMP2 activation. Suppression of a,,/MMP2 interaction by exogenously applied recombinant MMP2 PEX domain was shown previously to impair angiogenesis in animal models. Therefore, we examined the effects of : Compound 1 on growth factor-induced angiogenesis on the 10 day old chick
CAM. Application of Compound 1 to CAMs that had been stimulated with basic fibroblast growth factor (bFGF) almost completely abolished the development of new blood vessels in response to this stimuli (FIG. 4 A & 4B), while the control
Compound 12 was ineffective in this regard. Importantly, the abrogation of angiogenic infiltration in response to Compound 1 was not associated with suppression of MMP? activation since equivalent levels of active MMP2 (62 kDa) were detected in CAM tissues from treated and untreated embryos (FIG. 4C).
This is in stark contrast to the effect of exogenous MMP2 PEX domain, which suppressed MMP2 activation in this system. These data are consistent with the . notion that Compound 1 specifically interferes with the binding of MMP2 to integrin e f;, without impacting the activation of MMP2 directly. Indeed, the overall levels of MMP2 observed in the CAM lysates were unaffected by
Compound 1 treatment as well, ruling outa potential effect on the expression level of MMP2 in the angiogenic tissues (FIG. 4C). These results suggest that - the antiangiogenic effects of Compound 1 are likely due to the suppression of
MMP2 binding to integrin o,f; on the cell surface as demonstrated in Figure 3B.
These data also indicate that MMP2 which is fully activated is not utilized for angiogenesis in this system unless coupled to integrin «,B; on the cell surface.
Compound 1 abrogates tumor growth in vivo. Disruption of angiogenesis has been shown to inhibit tumor growth in numerous systems. As a result, blocking the invasive properties of endothelial cells by inhibiting MMPs suppresses angiogenesis and tumor growth in animal models as well. In fact, a number of MMP inhibitors have shown promise as anti-angiogenic agents in man.
Therefore, we assessed whether the inhibition of angiogenesis associated with blockade of MMP2/c. BB; interactions observed in this study might be sufficient to suppress the growth of an «, 3;-negative tumor. The use of the a, p;-negative tumor allowed the assessment of Compound 1's effect on vascular «.f3; selectively. As shown in FIG. 5A, growth of transplanted co, 3;-negative CS-1 melanoma tumors on the chick CAM was significantly retarded by a single intravenous (IV) injection of Compound 1, as was tumor weight (FIG. 5B). Itis likely that this effect was not due to a direct impact of Compound 1 on the tumor as the melanoma cells used in this assay lack integrin o,;. In fact, their growth in vitro is not affected by co-culture with the compound (data not shown). A gross reduction in the surface vasculature (FIG. SA) as well as the overall blood vessel density (FIG. 5C) was evident in the tumors that had been treated with
Compound 1. Importantly, this reduction in tumor vasculature was associated with significant cell death within the tumor mass, even as the control tumors showed a 6-fold increase in mass during the 10-day time frame of the assay.
The foregoing description and the Examples are to be taken as illustrative but not limiting. Still other variants within the spirit and scope of the present invention are possible and will readily present themselves to those skilled in the art.
Claims (71)
1. A compound of structure: : lo] 0} 1 ¥ yp on TI L NP ~ Y! &2 0) Oo a 10° t wherein G' and G? are each independently -NH-C(0)-O-R?, -NH-C(0)-O~CH,),-(C;H,)-X', -NH-C(0)-NH-(CH,),-(C¢H,)-X', -0-C(0)-NH-(CH,),~(C,H)-X!, -0-C(0)-0-(CH,),~(C.H,)-X', or -NH-C(0)-CH,~(C,H,)-X'; Y! and Y? are each independently OH, C;- C, alkyl, C;- C, hydroxyalkyl, C,- C, alkoxy, phenyl, benzyl, or -NH,; R! is C,- C, alkyl; X! is halo, nitro, C,- C, alkyl, C,- C, alkoxy, or C,- C, perfluoroalkyl; Z is -C=C-, -C(H,-, cis -CH=CH-, trans -CH =CH-, cis -CH,-CH =CH-CH,-, trans -CH,-CH=CH-CH,-, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3-cyclohexyl, cis- 1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each independently an integer having a value of O or 1; t is an integer having a value of 0 or 1; and v is an integer having a value of 1 or 2; with provisos that when A is H, t is 0; when A is a covalent bond, tis 1; whenm is 0, Y' is C,- C, hydroxyalkyl; and when n is 0, Y? is C, - C, hydroxyalkyl.
2. The compound of claim 1 wherein G' and G* are -NH-C(0)-0-(CH,),-(C,H)-X', A is a covalent bond, and v is 1.
3. The compound of claim 2 wherein X' is trifluoromethyl.
4. The compound of claim 2 wherein Y' ard Y? are OH, m is 1 and nis 1.
5. A compound of structure: : lo oN 0}
R. AAI Cy N i R? ~ y \r Ts hel 0 : 0 N° SX 3 t Xe wherein R? and R® are each independently H, C, - C, alkyl, phenyl or benzyl; X* and X? are each independently halo, nitro, C, - C, alkoxy, C, - C, alkyl, or C, - C, perfluoroalkyl; A is H or a covalent bond; and t is an integer having a value of 0 or 1; with the proviso that when A is H, t is 0 and when A is a covalent bond, t is 1.
6. The compound of claim 5 wherein at least one of X* and X’ is para-trifluoromethyl, and A is a covalent bond.
7. The compound of claim 5 wherein at least one of R? and R® is H, and A is a covalent bond.
8. The compound of claim 5 wherein at least one of R? and R’ is methyl, and A is a covalent bond. :
9. The compound of claim 5 wherein X* and X? are each para- trifluoromethyl, R? and R® are each methyl, and A is a covalent bond. :
10. The compound of claim 5 wherein R? is H, and A is H.
11. The compound of claim 5 wherein R? is methyl, and A is H.
12. The compound of claim 5 wherein X? is para-trifluoromethyl, R'is H, and A is H.
13. The compound of structure: 0 0 y OY NH lo EO Re NPs _H 3 : oy : 0 HN . ! | I Fa CFs 10° .
14. A pharmaceutical preparation comprising a compound of structure: o] 0] SP J } i C SN 2 H H Y hy NA Y' ni m & © © g' t wherein G! and G? are each independently -NH-C(0)-O-R!, -NH-C(0)-O-(CH,),{CH,)>-X", -NH-C(0)-NH-(CH),-(CH)-X!, : -0-C(0)-NH-(CH,),(C.H,)-X", -O-C(0)-0-(CH,),-(CiH)-X!, or -NH-C(0)-CH,-(C¢H,)-X"; Y' and Y? are each independently OH, C,- C, alkyl, C,- C, hydroxyalkyl, C,- C, alkoxy, phenyl, benzyl, or -NH,; R' is C,- C, alkyl; X! is halo, nitro, C,- C, alkyl, C,- C, alkoxy, or C,- C, perfluoroalkyl; Z is -C=C-, -CH,-, cis -CH=CH-, trans -CH=CH-, cis -CH,-CH=CH-CH,-, trans -CH,-CH=CH-CH,-, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3-cyclohexyl, cis- 1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each independently an integer having a value of O or 1; t is an integer having a value of 0 or 1; and v is an integer having a value of 1 or 2; with provisos that
PCT/US01/09756 ® Cm when A is H, t is 0; when A is a covalent bond, t is 1; when m is 0, Y' is C; - C, . hydroxyalkyl; and when n is 0, Y? is C, - C, hydroxyalkyl; in a pharmaceutically acceptable carrier.
15. The pharmaceutical preparation of claim 14 wherein G' and G? are -NH-C(0)-0«(CH,),~(CH)-X', A is a covalent bond, and v is 1.
16. The pharmaceutical preparation of claim 15 wherein X' is trifluoromethyl.
17. The pharmaceutical preparation of claim 15 wherein Y' and Y?are OH, mis 1 and nis 1. 10°
18. The pharmaceutical preparation of claim 15 wherein X? is ~ para-trifluoromethyl, R'is H, and A is H.
19. The pharmaceutical preparation comprising a compound of structure: 0 0 NH fo SSSNLACS NS a NH ol 0 HN, o CFs CFs : in a pharmaceutically acceptable carrier.
20. Use of a compound represented by the formula: AMENDED SHEET
PCT/US01/09756 ® - 44 - 0 [0] . SUVS Su SUSY 1 Y nti . Nr m Y t wherein G! and G? are each independently -NH-C(0O)-O-R!, -NH-C(0)-O-(CH,),- (C¢H,)-X',-NH-C(0)-NH-(CH,),-(C4H,)-X',-0-C(0)-NH-(CH,),-(C¢H,)-X",-O-C(0)- 0-(CH,),-(C{H,)-X', or -NH-C(0)-CH,-(C¢H,)-X"; Y' and Y? are each independently OH, C, - C, alkyl, C, - C, hydroxyalkyl, C, - C, alkoxy, phenyl, benzyl, or -NH,; R' is C, - C, alkyl; X' is halo, nitro, C, - C, alkyl, C, - C, alkoxy, or C, - C, perfluoroalkyl; Z is -C=C-, -CH,-, cis -CH=CH-, trans -CH=CH-, cis -CH,- CH =CH-CH,-, trans -CH,-CH =CH-CH,-, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3- cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each independently an integer having a value of 0 or 1; tis an integer having a value of 0 or 1; and v is an integer having a value of 1 or 2; with provisos that when A is H, tis 0; when A is a covalent bond, tis 1; whenm is 0, Y'is C, - C, hydroxyalkyl; and when n is 0, Y? is C, - C, hydroxyalkyl in the manufacture of a medicament for inhibiting tumor growth in a host by administering a therapeutically effective amount of said medicament to a host in need of such an inhibition.
21. Use of claim 20 wherein G' and G* are -NH-C(0)-O-(CH,),- (CH,)-X!, A is a covalent bond, and v is 1.
22. Use of claim 21 wherein X' is trifluoromethyl.
23. Use of claim 21 wherein Y' and Y? are OH, mis 1 and n is 1.
24. Use according to claim 20 wherein the administering comprises intraperitoneal, subcutaneous, intravenous, transdermal, intrasynovial, intramuscular or oral administration.
25. Use of a compound represented by the formula: AMENDED SHEET
) PCT/US01/09756 @® _ 45 - lo] o ’ 0 ” TOY 0 Se ane dai aad RH 0 0 "y : Y & CFs CFs in the manufacture of a medicament for inhibiting tumor growth in a host by administering a therapeutically effective amount of said medicament to a host in need of such inhibition.
26. Use according to claim 25 wherein the administering comprises intraperitoneal, subcutaneous, intravenous, transdermal, intrasynovial, intramuscular or oral administration.
27. Use of a compound represented by the formula: 0] 0] JI: J Ny fn AL Y ni NN m Y t wherein G' and G? are each independently -NH-C(0)-O-R', -NH-C(0)-O-(CH,),- (C¢H,)-X',-NH-C(0)-NH-(CH,),-(C(H,)-X', -0-C(0)-NH-(CH,),~(C¢H,)-X',-O-C(0O)- 0-(CH,),-(C¢H,)-X', or -NH-C(0)-CH,-(C¢H,)-X"; Y' and Y? are each independently OH, C, - C, alkyl, C, - C, hydroxyalkyl, C, - C, alkoxy, phenyl, benzyl, or -NH,; R' is C, - C, alkyl; X' is halo, nitro, C, - C, alkyl, C, - C, alkoxy, or C, - C, perfluoroalkyl; Z is -C=C-, -C¢H,-, cis -CH=CH-, trans -CH=CH-, cis -CH,- CH =CH-CH,-, trans -CH,-CH=CH-CH,-, 1,4-naphthyl, cis-1,3-cyciohexyl, trans-1, 3- cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each independently an integer having a value of 0 or 1; tis an integer having a value of O or 1; and v is an integer having a value of 1 or 2; with provisos that when A is H, tis 0; when A is a covalent bond, tis 1; whenm is 0, Y' is C, - C, hydroxyalkyl; and when nis 0, Y?is C, - C, hydroxyalkyl, in the manufacture of AMENDED SHEET
PCT/US01/09756 ¢ - 46 - a medicament for inhibiting angiogenesis in a tumor tissue by administering an angiogenesis inhibiting effective amount of said medicament to the tumor tissue.
28. Use according to claim 27 wherein G' and G? are -NH-C(0)-O- (CH,),-(CH,)-X', A is a covalent bond, and v is 1.
29. Use of claim 28 wherein X! is trifluoromethyl.
30. Use of claim 28 wherein Y'! and Y? are OH, mis 1 and nis 1.
31. Use according to claim 27 wherein the administering comprises intraperitoneal, subcutaneous, intravenous, transdermal, intrasynovial, intramuscular or oral administration.
32. Use of a compound represented by the formula: o] lo) NERY L Ny mn”
t . wherein G! and G? are each independently -NH-C(0)-O-R!, -NH-C(0)-O-(CH,),- (CsH)-X', -NH-C(0)-NH-(CH,),-(CH,)-X', -O-C(0)-NH-(CH,),~(C,H,)-X',-O-C(O)- 0-(CH,),-(CsH,)-X!, or -NH-C(0)-CH,-(C4H,)-X'; Y! and Y? are each independently OH, C, - C, alkyl, C, - C, hydroxyalkyl, C, - C, alkoxy, phenyl, benzyl, or -NH,; R!' is C, - C, alkyl; X' is halo, nitro, C, - C, alkyl, C, - C, alkoxy, or C, - C, perfluoroalkyl; Z is -C=C-, -CiH,-, cis -CH=CH-, trans -CH=CH-, cis -CH,- CH =CH-CH,-, trans -CH,-CH =CH-CH,-, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3- cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond, m and n are each independently an integer having a value of O or 1; tis an integer having a value of 0 or 1; and v is an integer having a value of 1 or 2; with provisos that when A is H, t is 0; when A is a covalent bond, tis 1; whenm is 0, Y'is C, - C, hydroxyalkyl; and when nis 0, Y? is C, - C, hydroxyalkyl, in the manufacture of a medicament for inducing apoptosis in tumor cells by administering a therapeutically effective amount of said medicament to the tumor cells. AMENDED SHEET
PCT/US01/09756
33. Use of claim 32 wherein G' and G? are -NH-C(0)-O-(CH,),- (C¢H)-X!, A is a covalent bond, and v is 1.
34. Use of claim 33 wherein X! is trifluoromethyl.
35. Use of claim 33 wherein Y! and Y> are OH, mis 1 and n is 1.
36. Use according to claim 32 wherein the administering comprises intraperitoneal, subcutaneous, intravenous, transdermal, intrasynovial, intramuscular or oral administration.
37. A method of inhibiting the interaction of MMP2 with integrin «8, in a host cell which comprises contacting the integrin with an interaction inhibiting amount of a compound represented by the formula: Oo _ SP: ] i C SO ? ER v Ny m 22 lo) lo] G' t wherein G' and G? are each independently -NH-C(0O)-O-R!, -NH-C(0)-O-(CH,),- (C¢Hy)-X!,-NH-C(0)-NH-(CH,),-(CsH,)-X!, -O-C(0)-NH-(CH,),-(C¢H,)-X!,-O-C(0)- 0-(CH,),-(C¢H,)-X', or -NH-C(0)-CH,(C,H,)-X"; Y' and Y? are each independently OH, C, - C, alkyl, C, - C, hydroxyalkyl, C, - C, alkoxy, phenyl, benzyl, or -NH,; R! is C, - C, alkyl; X! is halo, nitro, C, - C4 alkyl, C, - C, alkoxy, or C, - C, perfluoroalkyl; Z is -C=C-, -CiH,-, cis -CH=CH-, trans -CH=CH-, cis -CH,- CH =CH-CH,-, trans -CH,-CH =CH-CH,-, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3- cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond, m and n are each independently an integer having a value of 0 or 1; t is an integer having a value of O or 1; and v is an integer having a value of 1 or 2; with provisos that when A is H, t is 0; when A is a covalent bond, tis 1; whenm is 0, Y'is C, - C, hydroxyalkyl; and when n is 0, Y? is C, - C, hydroxyalkyl.
38. The method of claim 37 wherein G' and G? are -NH-C(O)-O- (CH,),-(C(H,)-X!, A is a covalent bond, and v is 1. AMENDED SHEET
PCT/US01/09756 Q - 48 -
39. The method of claim 38 wherein X' is trifluoromethyl.
40. The method of claim 38 wherein Y' and Y? are OH, mis 1 and n is 1.
41. Use of a compound as defined in claim 37 in the manufacture of a medicament for inhibiting the interaction of MMP2 with integrin «8; in a host cell by contacting the integrin with an interaction inhibiting amount of said medicament.
42. Use of claim 41 wherein G' and G* are -NH-C(0)-O-(CH,),- (CeH))-X!, A is a covalent bond, and v is 1.
43. Use of claim 42 wherein X' is trifluoromethyl.
44. Use of claim 42 wherein Y' and Y? are OH, mis 1 and nis 1.
45. A substance or composition for use in a method of inhibiting tumor growth in a host, said substance or composition comprising a compound as defined in claim 20, and said method comprising administering a therapeutically effective amount of said substance or composition to the host in need of such an inhibition.
46. A substance or composition for use in a method of treatment of claim 45 wherein G' and G? are -NH-C(0)-0-(CH,),-(C¢H,)-X', A is a covalent bond, and v is 1.
47. A substance or composition for use in a method of treatment of claim 46 wherein X! is trifluoromethyl.
48. A substance or composition for use in a method of treatment of claim 46 wherein Y' and Y2 are OH, mis 1 and n is 1.
49. A substance or composition for use in a method of treatment according to claim 45 wherein the administering comprises intraperitoneal, subcutaneous, intravenous, transdermal, intrasynovial, intramuscular or oral administration.
50. A substance or composition for use in a method of inhibiting tumor growth in a host, said substance or composition comprising a compound as defined in claim 25, and said method comprising administering a therapeutically effective amount of said substance or composition to the host in need of such an inhibition.
51. A substance or composition for use in a method of treatment according to claim S50 wherein the administering comprises intraperitoneal, subcutaneous, intravenous, transdermal, intrasynovial, intramuscular or oral administration. AMENDED SHEET
PCT/US01/09756 @
52. A substance or composition for use in a method of inhibiting angiogenesis in a tumor tissue, said substance or composition comprising a compound as defined in claim 27, and said method comprising administering an angiogenesis inhibiting effective amount of said substance or composition to the tumor tissue.
53. A substance or composition for use in a method of treatment of claim 52 wherein G' and G? are -NH-C(0)-O-(CH,),-(C¢H,)-X!, A is a covalent bond, and v is 1.
54. A substance or composition for use in a method of treatment of claim 53 wherein X! is trifluoromethyl.
55. A substance or composition for use in a method of treatment of claim 53 wherein Y' and Y? are OH, mis 1 and nis 1.
56. A substance or composition for use in a method of treatment according to claim 52 wherein the administering comprises intraperitoneal, subcutaneous, intravenous, transdermal, intrasynovial, intramuscular or oral administration.
57. A substance or composition for use in a method of inducing apoptosis in tumor cells, said substance or composition comprising a compound as defined in claim 32, and said method comprising administering a therapeutically effective amount of said substance or composition to the tumor cells.
58. A substance or composition for use in a method of treatment of claim 57 wherein G' and G? are -NH-C(0)-O-(CH,),-(C¢H,)-X!, A is a covalent bond, and v is 1.
59. A substance or composition for use in a method of treatment of claim 58 wherein X' is trifluoromethyl.
60. A substance or composition for use in a method of treatment of claim 58 wherein Y' and Y? are OH, mis 1 and nis 1.
61. A substance or composition for use in a method of treatment according to claim 57 wherein the administering comprises intraperitoneal, subcutaneous, intravenous, transdermal, intrasynovial, intramuscular or oral administration.
62. A substance or composition for use in a method of inhibiting the interaction of MMP2 with integrin «8, in a host cell, said substance or composition AMENDED SHEET
PCT/US01/09756 <P - 50 - comprising a compound as defined in claim 37, and said method comprising contacting the integrin with an interaction inhibiting amount of said substance or composition.
63. A substance or composition for use in a method of treatment of claim 62 wherein G' and G? are -NH-C(0)-O-(CH,),-(C¢H,)-X', A is a covalent bond, and v is 1.
64. A substance or composition for use in a method of treatment of claim 63 wherein X' is trifluoromethyl.
65. A substance or composition for use in a method of treatment of claim 63 wherein Y! and Y? are OH, mis 1 and nis 1.
66. A compound according to claim 1, or claim 5, or claim 13, substantially as herein described and illustrated.
67. A preparation according to claim 14, or claim 19, substantially as herein described and illustrated.
68. Use according to claim 20, or claim 25, or claim 27, or claim 32, or claim 41, substantially as herein described and illustrated.
69. A method according to claim 37, substantially as herein described and illustrated.
70. A substance or composition for use in a method of treatment according to claim 45, or claim 50, or claim 52, or claim 57, or claim 62, substantially as herein described and illustrated.
71. A new compound; a new preparation; a new use of a compound as defined in any of claims 20, 25, 27, 32, or 41; a new non-therapeutic method of treatment; or a substance or composition for a new use in a method of treatment, ] substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19226000P | 2000-03-27 | 2000-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200208628B true ZA200208628B (en) | 2004-02-12 |
Family
ID=22708924
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200208628A ZA200208628B (en) | 2000-03-27 | 2002-10-24 | Inhibition of angiogenesis and tumor growth. |
ZA200208626A ZA200208626B (en) | 2000-03-27 | 2002-10-24 | Methods for inhibiting angiogenesis and tumor growth. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200208626A ZA200208626B (en) | 2000-03-27 | 2002-10-24 | Methods for inhibiting angiogenesis and tumor growth. |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP1272173A4 (en) |
JP (2) | JP2003528850A (en) |
KR (2) | KR100767616B1 (en) |
CN (2) | CN1229339C (en) |
AU (4) | AU5101801A (en) |
CA (3) | CA2659030A1 (en) |
CZ (2) | CZ20023510A3 (en) |
HU (2) | HUP0301621A3 (en) |
MX (2) | MXPA02009510A (en) |
NO (2) | NO328969B1 (en) |
PL (2) | PL358272A1 (en) |
RU (2) | RU2276133C2 (en) |
SK (2) | SK14852002A3 (en) |
WO (2) | WO2001072699A1 (en) |
ZA (2) | ZA200208628B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2315721T5 (en) | 2003-10-23 | 2012-08-24 | Otsuka Pharmaceutical Co., Ltd. | Formulation of sterile controlled-release injectable aripiprazole and procedure |
UA97286C2 (en) | 2007-07-31 | 2012-01-25 | Оцука Фармасьютикал Ко., Лтд. | Method for producing an aripiprazole suspension and freeze-dried formulation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8311286D0 (en) * | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
JPH05125029A (en) | 1991-11-06 | 1993-05-21 | Yamanouchi Pharmaceut Co Ltd | New amide compound or its salt |
GB9308695D0 (en) * | 1993-04-27 | 1993-06-09 | Celltech Ltd | Peptidyl derivatives |
GB9405076D0 (en) * | 1994-03-16 | 1994-04-27 | Inst Of Ophtalmology | A medical use of matrix metalloproteinase inhibitors |
AUPO104496A0 (en) * | 1996-07-17 | 1996-08-08 | Biomolecular Research Institute Limited | Angiogenic inhibitory compounds |
KR20000068415A (en) * | 1996-09-04 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Compounds for and a Method of Inhibiting Matrix Metalloproteinase |
EP0968423A4 (en) * | 1997-02-07 | 2002-10-30 | Scripps Research Inst | Convergent synthesis of combinatorial library |
KR100596109B1 (en) * | 1998-03-27 | 2006-07-05 | 제넨테크, 인크. | Antagonists for Treatment of CD11/CD18 Adhesion Receptor Mediated Disorders |
-
2001
- 2001-03-27 HU HU0301621A patent/HUP0301621A3/en unknown
- 2001-03-27 AU AU5101801A patent/AU5101801A/en active Pending
- 2001-03-27 KR KR1020027012724A patent/KR100767616B1/en not_active IP Right Cessation
- 2001-03-27 KR KR1020027012720A patent/KR100776185B1/en not_active IP Right Cessation
- 2001-03-27 SK SK1485-2002A patent/SK14852002A3/en not_active Application Discontinuation
- 2001-03-27 SK SK1484-2002A patent/SK14842002A3/en not_active Application Discontinuation
- 2001-03-27 WO PCT/US2001/009756 patent/WO2001072699A1/en active IP Right Grant
- 2001-03-27 EP EP01922734A patent/EP1272173A4/en not_active Withdrawn
- 2001-03-27 WO PCT/US2001/009785 patent/WO2001072297A1/en active IP Right Grant
- 2001-03-27 AU AU2001249499A patent/AU2001249499B2/en not_active Ceased
- 2001-03-27 CN CNB018097448A patent/CN1229339C/en not_active Expired - Fee Related
- 2001-03-27 JP JP2001570612A patent/JP2003528850A/en active Pending
- 2001-03-27 RU RU2002128751/04A patent/RU2276133C2/en not_active IP Right Cessation
- 2001-03-27 RU RU2002128736/15A patent/RU2269339C2/en not_active IP Right Cessation
- 2001-03-27 CZ CZ20023510A patent/CZ20023510A3/en unknown
- 2001-03-27 EP EP01924359A patent/EP1276713A4/en not_active Ceased
- 2001-03-27 MX MXPA02009510A patent/MXPA02009510A/en active IP Right Grant
- 2001-03-27 CN CNB01809743XA patent/CN1245967C/en not_active Expired - Fee Related
- 2001-03-27 PL PL01358272A patent/PL358272A1/en not_active Application Discontinuation
- 2001-03-27 PL PL366316A patent/PL205134B1/en not_active IP Right Cessation
- 2001-03-27 CA CA002659030A patent/CA2659030A1/en not_active Abandoned
- 2001-03-27 CZ CZ20023509A patent/CZ20023509A3/en unknown
- 2001-03-27 MX MXPA02009504A patent/MXPA02009504A/en active IP Right Grant
- 2001-03-27 JP JP2001570258A patent/JP2003528140A/en not_active Withdrawn
- 2001-03-27 AU AU4949901A patent/AU4949901A/en active Pending
- 2001-03-27 CA CA002403630A patent/CA2403630C/en not_active Expired - Fee Related
- 2001-03-27 CA CA2403871A patent/CA2403871C/en not_active Expired - Fee Related
- 2001-03-27 AU AU2001251018A patent/AU2001251018B2/en not_active Ceased
- 2001-03-27 HU HU0301797A patent/HUP0301797A3/en unknown
-
2002
- 2002-09-24 NO NO20024578A patent/NO328969B1/en not_active IP Right Cessation
- 2002-09-24 NO NO20024576A patent/NO20024576L/en not_active Application Discontinuation
- 2002-10-24 ZA ZA200208628A patent/ZA200208628B/en unknown
- 2002-10-24 ZA ZA200208626A patent/ZA200208626B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7249374B2 (en) | Compositions, Formulations and Methods for Treating Eye Diseases | |
KR100194242B1 (en) | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treating inflammatory diseases of the eye | |
JP2020125355A (en) | Combination therapy | |
KR20010022499A (en) | Acyclic metalloprotease inhibitors | |
RU2696581C2 (en) | Derivatives of n-urea-substituted aminoacids as modulators of formyl-peptide receptor | |
KR20000035925A (en) | Phosphinic acid amides as matrix metalloprotease inhibitors | |
US7368478B2 (en) | Methods for inhibiting angiogenesis and tumor growth | |
RU2703725C1 (en) | Phenylcarbamate derivatives as formyl peptide receptor modulators | |
AU2006285177A1 (en) | EP2 receptor agonists for treating glaucoma | |
EP1284265A1 (en) | Benzothiophene derivatives and medicinal use thereof | |
AU2001251018B2 (en) | Inhibition of angiogenesis and tumor growth | |
US6803383B2 (en) | Inhibition of angiogenesis and tumor growth | |
AU2001251018A1 (en) | Inhibition of angiogenesis and tumor growth | |
AU2001249499A1 (en) | Methods for inhibiting angiogenesis and tumor growth | |
CA3162689A1 (en) | Combinations of tie-2 activators and prostaglandins and uses thereof | |
AU2013200669A1 (en) | EP2 receptor agonists for treating glaucoma |